CANNAINVESTOR Magazine U.S. Publicly Traded May/June 2018 | Page 63

$57B

63

The last month has been sobering after the spectacular run up to the end of 2017 that extended into the early days of 2018.

You may be thinking aloud “wait a minute, I can identify a few on that list where cannabis has shown to be effective in treating …”. I am referring to absolute medical proof where doctors can universally point to a body of knowledge grown out of clinical trials that can be validated, repeated, replicated, and collaborated and that meet all the criteria inherent to the clinical trial process and therefore to be able to recommend or prescribe. So again, I say to you, imagine if just one of those conditions (or any of the many not listed) is medically demonstrated to be effectively treated by cannabis? Whether you invest on the secondary market, through private placements and similar offerings, work in the industry, or have your own company (or planning to) … you know what such a conclusion could mean. Now imagine two of those medical conditions … now three … now more. Diabetes alone is an interesting one because not only is cannabis showing early signs of being an effective treatment but there are other conditions/diseases on that list that diabetes can lead to that are also showing preliminary positive results from cannabis – blood pressure, Alzheimer’s, vision deterioration, mental alertness, fatigue, chronic pain, and so forth.

2027